Biodesix Confirms Prognostic Value of VeriStrat Testing in Phase 3 Study of Patients with Advanced Lung Cancer
A new study published in the Oncologist demonstrates the objective prognostic value of the Biodesix VeriStrat® test in patients with non-small cell lung cancer
Biodesix announced that it has acquired Integrated Diagnostics, Inc.
Society for Advanced Bronchoscopy Commits to Enhance Education and Practice Excellence as U.S. Demand for Bronchoscopy Procedures Increases
Bronchoscopy professionals in the United States need greater educational and practice-building support to ensure continued delivery of high-quality care for Americans
The Society for Advanced Bronchoscopy (SAB) will hold its second meeting: Hot Topics in Advanced Bronchoscopy.
New Data Demonstrate the Biodesix VeriStrat® Liquid Biopsy Test Reliably Informs Lung Cancer Treatment Decisions
New data demonstrate that a blood-based proteomic test reliably assesses individual patient prognosis to inform treatment decisions.
Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex
Biodesix Raises Add-On to Series G, Enters into Debt Refinancing Agreement with Innovatus Capital Partners; Scott Hutton Joins Biodesix
Innovatus Capital partners joins as a new investor; Scott Hutton joins as COO
Biodesix and Professor Fred R. Hirsch announced a collaboration on a PD-L1 study
Media Advisory: Dr. Heinrich Roder, Biodesix CTO, to speak at precision medicine world conference
Data Published In AACR Journal Suggest Biodesix® Test in Development May Identify Melanoma Patients Who Could Benefit from Checkpoint Inhibitors
Findings in the AACR Journal on melanoma patient outcomes after anti PD1 therapy; a serum protein signature predicted survival.